192 related articles for article (PubMed ID: 23301673)
1. PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1.
Pinton G; Manente AG; Murer B; De Marino E; Mutti L; Moro L
J Cell Mol Med; 2013 Feb; 17(2):233-41. PubMed ID: 23301673
[TBL] [Abstract][Full Text] [Related]
2. PARP inhibition induces Akt-mediated cytoprotective effects through the formation of a mitochondria-targeted phospho-ATM-NEMO-Akt-mTOR signalosome.
Tapodi A; Bognar Z; Szabo C; Gallyas F; Sumegi B; Hocsak E
Biochem Pharmacol; 2019 Apr; 162():98-108. PubMed ID: 30296409
[TBL] [Abstract][Full Text] [Related]
3. MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer.
Tian S; Lou L; Tian M; Lu G; Tian J; Chen X
J Exp Clin Cancer Res; 2020 Jul; 39(1):143. PubMed ID: 32711558
[TBL] [Abstract][Full Text] [Related]
4. Asbestos exposure affects poly(ADP-ribose) polymerase-1 activity: role in asbestos-induced carcinogenesis.
Tomasetti M; Amati M; Nocchi L; Saccucci F; Strafella E; Staffolani S; Tarquini LM; Carbonari D; Alleva R; Borghi B; Neuzil J; Bracci M; Santarelli L
Mutagenesis; 2011 Sep; 26(5):585-91. PubMed ID: 21543585
[TBL] [Abstract][Full Text] [Related]
5. mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma.
Annovazzi L; Mellai M; Caldera V; Valente G; Tessitore L; Schiffer D
Anticancer Res; 2009 Aug; 29(8):3087-94. PubMed ID: 19661320
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
7. SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1.
Rajamohan SB; Pillai VB; Gupta M; Sundaresan NR; Birukov KG; Samant S; Hottiger MO; Gupta MP
Mol Cell Biol; 2009 Aug; 29(15):4116-29. PubMed ID: 19470756
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose) polymerase 1-sirtuin 1 functional interplay regulates LPS-mediated high mobility group box 1 secretion.
Walko TD; Di Caro V; Piganelli J; Billiar TR; Clark RS; Aneja RK
Mol Med; 2015 Mar; 20(1):612-24. PubMed ID: 25517228
[TBL] [Abstract][Full Text] [Related]
9. Thrombomodulin is silenced in malignant mesothelioma by a poly(ADP-ribose) polymerase-1-mediated epigenetic mechanism.
Nocchi L; Tomasetti M; Amati M; Neuzil J; Santarelli L; Saccucci F
J Biol Chem; 2011 Jun; 286(22):19478-88. PubMed ID: 21489980
[TBL] [Abstract][Full Text] [Related]
10. Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma.
Morra F; Merolla F; D'Abbiero D; Ilardi G; Campione S; Monaco R; Guggino G; Ambrosio F; Staibano S; Cerrato A; Visconti R; Celetti A
Lung Cancer; 2019 Sep; 135():56-65. PubMed ID: 31447003
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-ribose) polymerase 1 is involved in glucose toxicity through SIRT1 modulation in HepG2 hepatocytes.
Pang J; Gong H; Xi C; Fan W; Dai Y; Zhang TM
J Cell Biochem; 2011 Jan; 112(1):299-306. PubMed ID: 21031461
[TBL] [Abstract][Full Text] [Related]
12. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
[TBL] [Abstract][Full Text] [Related]
13. PARP1 inhibitors attenuate AKT phosphorylation via the upregulation of PHLPP1.
Wang S; Wang H; Davis BC; Liang J; Cui R; Chen SJ; Xu ZX
Biochem Biophys Res Commun; 2011 Aug; 412(2):379-84. PubMed ID: 21821012
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib.
Pinton G; Thomas W; Bellini P; Manente AG; Favoni RE; Harvey BJ; Mutti L; Moro L
PLoS One; 2010 Nov; 5(11):e14110. PubMed ID: 21124760
[TBL] [Abstract][Full Text] [Related]
15. Poly(ADP-ribose) polymerase 1 is indispensable for transforming growth factor-β Induced Smad3 activation in vascular smooth muscle cell.
Huang D; Wang Y; Wang L; Zhang F; Deng S; Wang R; Zhang Y; Huang K
PLoS One; 2011; 6(10):e27123. PubMed ID: 22073128
[TBL] [Abstract][Full Text] [Related]
16. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells.
Mitchell C; Park M; Eulitt P; Yang C; Yacoub A; Dent P
Mol Pharmacol; 2010 Nov; 78(5):909-17. PubMed ID: 20696794
[TBL] [Abstract][Full Text] [Related]
18. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation.
Bai P; Cantó C; Oudart H; Brunyánszki A; Cen Y; Thomas C; Yamamoto H; Huber A; Kiss B; Houtkooper RH; Schoonjans K; Schreiber V; Sauve AA; Menissier-de Murcia J; Auwerx J
Cell Metab; 2011 Apr; 13(4):461-468. PubMed ID: 21459330
[TBL] [Abstract][Full Text] [Related]
19. Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.
Tobin LA; Robert C; Rapoport AP; Gojo I; Baer MR; Tomkinson AE; Rassool FV
Oncogene; 2013 Apr; 32(14):1784-93. PubMed ID: 22641215
[TBL] [Abstract][Full Text] [Related]
20. Sulforaphane ameliorates amyloid-β-induced inflammatory injury by suppressing the PARP1/SIRT1 pathway in retinal pigment epithelial cells.
Wang S; Tang YJ
Bioengineered; 2021 Dec; 12(1):7079-7089. PubMed ID: 34982643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
